ESC 365 - Transforming growth factor beta and fibroblast growth factor 21 in cardiovascular prognosis in patients with obesity and type 2 diabetes mellitus

ESC Premium Access

Transforming growth factor beta and fibroblast growth factor 21 in cardiovascular prognosis in patients with obesity and type 2 diabetes mellitus

Session: Poster session 6 - Diabetes

Topic: Diabetes, dysglycaemia and metabolic syndrome

Speaker: Doctor T. Shvangiradze (Moscow, RU)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Teona Shvangiradze

Endocrinology Research Center, Moscow (Russian Federation)

0 follower

14 more presentations in this session

Absence of QTc prolongation with semaglutide: a thorough QT/QTc study in healthy subjects.

Speaker: Doctor V. Demmel (Munchen, DE)

One year clinical outcome of biodegradable polymer sirolimus eluting stent in diabetes mellitus patients: insight from the ULISSE registry.

Speaker: Doctor C. Pivato (Milan, IT)

Increased left ventricular mass in non-hypertensive patients admitted with a first myocardial infarction and dysglycaemia by an oral glucose tolerance test

Speaker: Mr G. Pararajasingam (Svendborg, DK)

Serum c-reactive protein and urine albumin level associated with silent myocardial ischemia in patients with diabetes mellitus

Speaker: Mr Y. Honda (Gotemba, JP)

Single and combined effects of inflammatory markers on diabetes development; the mediating role of obesity: 10-year follow up of the ATTICA study

Speaker: Professor D. Panagiotakos (Athens, GR)

Access the full session

Poster session 6 - Diabetes

Speakers: Doctor T. Shvangiradze, Doctor V. Demmel, Doctor C. Pivato, Mr G. Pararajasingam, Mr Y. Honda...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources